Innovative Pharmaceutical Biotech (HKSE:00399) Net Cash per Share : HK$-1.01 (As of Sep. 2024)

Innovative Pharmaceutical Biotech Net Cash per Share Chart

Innovative Pharmaceutical Biotech Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24
Net Cash per Share		Get a 7-Day Free Trial					-1.22	-1.36	-1.33	-1.49	-1.16

Innovative Pharmaceutical Biotech Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Net Cash per Share	Get a 7-Day Free Trial															-1.40	-1.49	-1.35	-1.16	-1.01

Competitive Comparison of Innovative Pharmaceutical Biotech's Net Cash per Share

For the Specialty Retail subindustry, Innovative Pharmaceutical Biotech's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovative Pharmaceutical Biotech's Price-to-Net-Cash Distribution in the Retail - Cyclical Industry

For the Retail - Cyclical industry and Consumer Cyclical sector, Innovative Pharmaceutical Biotech's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Innovative Pharmaceutical Biotech's Price-to-Net-Cash falls into.

Innovative Pharmaceutical Biotech Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Innovative Pharmaceutical Biotech's Net Cash per Share for the fiscal year that ended in Mar. 2024 is calculated as

Innovative Pharmaceutical Biotech's Net Cash per Share for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovative Pharmaceutical Biotech  (HKSE:00399) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Innovative Pharmaceutical Biotech Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative Pharmaceutical Biotech Business Description